Literature DB >> 23591987

Antihypertensive prescriptions over a 10-year period in a large Chinese population.

Martin C S Wong1, Wilson W S Tam, Clement S K Cheung, Ellen L H Tong, Antonio C H Sek, N T Cheung, Bryan P Y Yan, Cheuk-Man Yu, Sian M Griffiths.   

Abstract

BACKGROUND: International guidelines recommending antihypertensive prescriptions for the management of hypertension have been published in the past decade. Beta-blocker use was discouraged by a significant body of evidence and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) were found more effective among younger patients. This study aims to evaluate the trends in prescription profiles in a large Chinese population because patterns of antihypertensive agent dispensation represent important information for physicians and policymakers.
METHODS: From clinical databases consisting of all patient records in the public health-care system of Hong Kong, we examined all antihypertensive prescriptions according to the drug classes (thiazide diuretics, alpha-blockers, beta-blockers, calcium channel blockers (CCBs), ACEIs, ARBs, fixed-dose combinations, and polytherapy (2, ≥3)) between 2001 and 2010. We retrieved >6.3 million prescription episodes for 223,287 patients.
RESULTS: The average age of the patients was 59.9 years (SD = 17.6), and 54.8% were women. According to prescription episodes, the most commonly prescribed medications were beta-blockers (31.7%) and CCBs (29.2%), followed by ACEIs (13.9%), thiazide diuretics (5.0%), and alpha-blockers (4.5%). Between 2001 and 2010, the prescription proportions of beta-blockers decreased from 41.5% to 21.5%, whereas that of ARBs increased from 0.5% to 1.0% (P < 0.001, χ(2) test for trend). It was found that the decline of beta-blockers (71.0% to 35.4%) and increase in ARB prescriptions (0.4% to 1.0%) were particularly marked among younger subjects aged <55 years.
CONCLUSIONS: These findings provided information on the prescription patterns of antihypertensive agents in a large Chinese population. It sets a future research direction to study the various reasons influencing these drug class-specific trends.

Entities:  

Keywords:  antihypertensive agents; blood pressure; drug class; evidence-based practice; hypertension; prescriptions trends.

Mesh:

Substances:

Year:  2013        PMID: 23591987     DOI: 10.1093/ajh/hpt049

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

1.  Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis.

Authors:  Mahin Delara; Lauren Murray; Behnaz Jafari; Anees Bahji; Zahra Goodarzi; Julia Kirkham; Mohammad Chowdhury; Dallas P Seitz
Journal:  BMC Geriatr       Date:  2022-07-19       Impact factor: 4.070

2.  The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis.

Authors:  Li-Ping Du; Zhong-Wei Cheng; Yu-Xuan Zhang; Ying Li; Dan Mei
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-27       Impact factor: 3.738

3.  Management of hypertension and diabetes mellitus by cardiovascular and endocrine physicians: a China registry.

Authors:  Jie Song; Chang-Sheng Sheng; Qi-Fang Huang; Li-Hua Li; Chang-Sheng Ma; Xiao-Hui Guo; Li-Nong Ji; Ji-Guang Wang
Journal:  J Hypertens       Date:  2016-08       Impact factor: 4.844

4.  Antihypertensive drugs use over a 5-year period among children and adolescents in Beijing, China: An observational study.

Authors:  Yao Wu; Yaying Cao; Jing Song; Yaohua Tian; Mengying Wang; Man Li; Xiaowen Wang; Zhe Huang; Lin Li; Yaling Zhao; Xueying Qin; Yonghua Hu
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.